California to sue Lilly, other drug companies over insulin prices
California on Thursday announced it will sue the companies that make and promote most of the nation’s insulin, accusing them of scheming to illegally increase the price of the drug.
Eli Lilly and Co.
Articles
Stories about Scott Wise, IMS and Lilly are IBJ’s most-read of 2022
The list—based on the number of times readers clicked on stories—includes several other real estate stories as well, including the future plans for Christel DeHaan’s former estate and a fitness chain’s plans to move into a former Marsh store.
With stock trading near record high, Lilly embarks on ambitious 2023
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
Diabetes drug Lilly abandoned has new life
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
Eli Lilly’s report card on racial justice effort shows $15.6M in donations
The Indianapolis-based drugmaker released a report card Thursday that outlined its progress “to support effective solutions” to racial inequity and social injustice. In addition to donations, the company has committed tens of millions of dollars to other diversity efforts.
A fake tweet sparked panic at Eli Lilly and may have cost Twitter millions
By Friday morning, Eli Lilly executives had ordered a halt to all Twitter ad campaigns—a potentially serious blow, given that the $330 billion company controls the kind of massive advertising budget that Musk says the company needs to avoid bankruptcy.
Roche’s Alzheimer’s drug fails in fresh blow to fraught field
Gantenerumab’s demise is a boost for Indianapolis-based Eli Lilly and Biogen, which are also developing treatments for Alzheimer’s, said Tim Anderson, an analyst at Wolfe Research. Lilly shares were up 1.8% at midday.
Twitter deals with users impersonating major companies—including Eli Lilly
A Twitter user posing as Indianapolis-based Eli Lilly falsely tweeted that insulin was now free, prompting an apology from the actual company.
Lilly shares stumble on lower profit outlook despite solid quarter
Eli Lilly stock has skyrocketed 36% in the past 52 weeks due to strong sales on newer drugs, but the market reacted negatively to its latest forecast.
Lilly commits $92.5M to Purdue for drug research, scholarships
In a significant expansion of their longstanding collaboration, the partners hope to develop new models for delivering therapies to patients and provide full tuition to between 75 and 100 students each year for 10 years.
Lebanon City Council approves water plan for Lilly project
The Lebanon City Council on Monday night approved an agreement that would reserve water and wastewater for a $2.1 billion Eli Lilly and Co. development in Boone County.
Lilly to acquire Boston-based gene therapy firm for $487M
The Indianapolis-based drugmaker said it has reached a definitive agreement to acquire Akouos Inc., a seven-year-old biotech firm, which is running early clinical trials for its lead therapy for hearing loss.
Coronavirus variant swarm could fuel winter surge
Any variant that winds up dominating in coming months will probably challenge a key line of treatment and protection for people with compromised immune systems—the drugs known as monoclonal antibodies.
Suit accuses Lilly of illegally deducting funds from paychecks for vehicle use, extra time off
The lawsuit was filed this month by a senior sales representative who worked for Eli Lilly for 11 years before resigning in June. The complaint seeks class-action status on behalf of thousand of employees and former employees of Lilly.
Going strong: U.S. dollar gained value against key currencies in past year
When the dollar is strong, a U.S.-based company that sells products overseas earns fewer dollars. On the flip side, the cost of imported goods and foreign expenses are lower.
Lilly lands Fast Track designation for potential blockbuster drug
Indianapolis-based Eli Lilly and Co. announced Thursday that it has received a Fast Track designation from the U.S. Food and Drug Administration to investigate its diabetes drug tirzepatide for the treatment of adults with obesity.
Q&A: Career path jumps from megacorp to small not-for-profit
Michele Sawyer started Sept. 1 as chief financial officer at the Indiana Biosciences Research Institute after more than two decades at drugmaker Eli Lilly and Co. and its animal health spinoff, Elanco Animal Health.
Indy Chamber exec joins developer working on Boone County innovation district
Ian Nicolini, who has served as Indy Chamber’s chief operating officer since October 2020, is leaving his position to join a commercial real estate developer working to recruit businesses to a high-tech research district planned in Boone County.
Insulin cap for Medicare patients signals hope for others
In January, the cost of insulin for patients on Medicare will be capped at $35 a month. But that cap doesn’t apply to those with private insurance, which is used by the majority of those in need of insulin.
Editorial: Impact of abortion ban demands review
Indiana ended up with a rushed law that seemed to please few.